Analytical Data
-
Gene name
PA2G4
- Application
-
Alternative Names
EBP1; HG4-1; p38-2G4; Cell cycle protein p38-2G4 homolog; ErbB3-binding protein 1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UQ80
-
Expression Region
Ser2~Asp394
-
Molecular Weight
47kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PA2G4, also known as p53-activated gene 4, is a protein that has garnered attention in the field of molecular biology due to its involvement in various cellular processes, including cell proliferation, differentiation, and apoptosis. Initially identified as a transcriptional regulator associated with the p53 tumor suppressor pathway, PA2G4 has been implicated in several types of cancer, as its expression levels can influence tumor growth and progression. Research has shown that PA2G4 interacts with other key cellular proteins and inhibits the activity of cyclin-dependent kinases, thereby playing a critical role in cell cycle regulation. Furthermore, its potential as a biomarker for cancer prognosis has spurred interest in understanding its functional mechanisms at the molecular level. Studies on PA2G4 also suggest its participation in the modulation of immune responses and its potential therapeutic implications in oncology. The recombinant production of PA2G4 provides valuable material for biochemical assays and structural studies, which can further elucidate its role in disease mechanisms and facilitate the development of targeted therapies. As a result, PA2G4 is a subject of ongoing research aimed at unraveling its complex biology and exploring its utility in clinical applications.
